David Taussig

5.1k total citations · 1 hit paper
56 papers, 3.2k citations indexed

About

David Taussig is a scholar working on Hematology, Molecular Biology and Immunology. According to data from OpenAlex, David Taussig has authored 56 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Hematology, 18 papers in Molecular Biology and 16 papers in Immunology. Recurrent topics in David Taussig's work include Acute Myeloid Leukemia Research (28 papers), Hematopoietic Stem Cell Transplantation (17 papers) and Immune Cell Function and Interaction (10 papers). David Taussig is often cited by papers focused on Acute Myeloid Leukemia Research (28 papers), Hematopoietic Stem Cell Transplantation (17 papers) and Immune Cell Function and Interaction (10 papers). David Taussig collaborates with scholars based in United Kingdom, United States and France. David Taussig's co-authors include Dominique Bonnet, John G. Gribben, T. Andrew Lister, Daniel J. Pearce, Farideh Miraki‐Moud, A. Z. S. Rohatiner, Fernando Anjos‐Afonso, Jamie Cavenagh, Heather Oakervee and Kirsty Allen and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nucleic Acids Research and Journal of Biological Chemistry.

In The Last Decade

David Taussig

51 papers receiving 3.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study

2016 336 citations Norbert Vey, Karen Yee et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Taussig United Kingdom	22	1.7k	1.6k	951	769	472	56	3.2k
Harald Herrmann Austria	27	1.4k 0.8×	2.1k 1.3×	647 0.7×	610 0.8×	206 0.4×	72	3.3k
Arjan Buijs Netherlands	18	1.3k 0.8×	1.8k 1.1×	857 0.9×	235 0.3×	347 0.7×	37	3.1k
Armando G. Poeppl Canada	7	922 0.6×	951 0.6×	534 0.6×	475 0.6×	383 0.8×	10	1.9k
Luke F. Peterson United States	26	862 0.5×	1.7k 1.1×	708 0.7×	374 0.5×	232 0.5×	66	2.4k
Kalindi Parmar United States	28	706 0.4×	2.1k 1.3×	862 0.9×	321 0.4×	586 1.2×	60	3.0k
Sylvie Freeman United Kingdom	27	2.0k 1.2×	1.5k 1.0×	535 0.6×	840 1.1×	292 0.6×	73	3.3k
Olivier Rosnet France	32	1.5k 0.9×	1.4k 0.8×	440 0.5×	599 0.8×	147 0.3×	52	2.9k
Katharina Blatt Austria	26	1.0k 0.6×	1.8k 1.1×	447 0.5×	407 0.5×	141 0.3×	58	3.2k
B. Douglas Smith United States	13	834 0.5×	899 0.6×	776 0.8×	285 0.4×	214 0.5×	23	1.6k
Claudia Voena Italy	29	992 0.6×	1.4k 0.9×	1.2k 1.3×	735 1.0×	359 0.8×	57	3.2k

Countries citing papers authored by David Taussig

Since Specialization

Citations

This map shows the geographic impact of David Taussig's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Taussig with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Taussig more than expected).

Fields of papers citing papers by David Taussig

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Taussig. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Taussig. The network helps show where David Taussig may publish in the future.

Co-authorship network of co-authors of David Taussig

This figure shows the co-authorship network connecting the top 25 collaborators of David Taussig. A scholar is included among the top collaborators of David Taussig based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Taussig. David Taussig is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cortés, Jorge Alberto, Antonio Curti, Pierre Fenaux, et al.. (2025). Olutasidenib for mutated IDH1 acute myeloid leukemia: final five-year results from the phase 2 pivotal cohort. Journal of Hematology & Oncology. 18(1). 102–102.

Gunasekaran, Dharanivasan, et al.. (2024). A dual-channel electrochemical biosensor enables concurrent detection of pathogens and antibiotic resistance. Biosensors and Bioelectronics. 257. 116314–116314. 11 indexed citations

Sekeres, Mikkael A., Pau Montesinos, Jan Novák, et al.. (2023). Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial. Leukemia. 37(10). 2017–2026. 15 indexed citations

Taussig, David, et al.. (2023). Antibody Isolation from Human Synthetic Libraries of Single-Chain Antibodies and Analysis Using NGS. Methods in molecular biology. 2702. 347–372.

Casado, Pedro, Ana Rio‐Machín, Juho J. Miettinen, et al.. (2023). Integrative phosphoproteomics defines two biologically distinct groups of KMT2A rearranged acute myeloid leukaemia with different drug response phenotypes. Signal Transduction and Targeted Therapy. 8(1). 80–80. 13 indexed citations

Vaisman‐Mentesh, Anna, David Taussig, Yael Dror, et al.. (2022). Longitudinal kinetics of RBD+ antibodies in COVID-19 recovered patients over 14 months. PLoS Pathogens. 18(6). e1010569–e1010569. 5 indexed citations

Halim, Leena, Farideh Miraki‐Moud, David Taussig, et al.. (2021). Priming Death Receptor Mediated Apoptosis with Arginine Starvation Sensitises Arginine Auxotrophic B-ALL to CAR-T. Blood. 138(Supplement 1). 2787–2787.

Moore, Andrew S., Amir Faisal, Grace Wing-Yan Mak, et al.. (2020). Quizartinib-resistant FLT3-ITD acute myeloid leukemia cells are sensitive to the FLT3-Aurora kinase inhibitor CCT241736. Blood Advances. 4(7). 1478–1491. 20 indexed citations

Ghazaly, Essam, Farideh Miraki‐Moud, Robert Petty, et al.. (2020). Repression of sphingosine kinase (SK)-interacting protein (SKIP) in acute myeloid leukemia diminishes SK activity and its re-expression restores SK function. Journal of Biological Chemistry. 295(16). 5496–5508. 7 indexed citations

10.

Waclawiczek, Alexander, Ashley Hamilton, Kevin Rouault‐Pierre, et al.. (2020). Mesenchymal niche remodeling impairs hematopoiesis via stanniocalcin 1 in acute myeloid leukemia. Journal of Clinical Investigation. 130(6). 3038–3050. 49 indexed citations

11.

Zeidan, Amer M., James D. Cavenagh, Maria Teresa Voso, et al.. (2019). Efficacy and Safety of Azacitidine (AZA) in Combination with the Anti-PD-L1 Durvalumab (durva) for the Front-Line Treatment of Older Patients (pts) with Acute Myeloid Leukemia (AML) Who Are Unfit for Intensive Chemotherapy (IC) and Pts with Higher-Risk Myelodysplastic Syndromes (HR-MDS): Results from a Large, International, Randomized Phase 2 Study. Blood. 134(Supplement_1). 829–829. 60 indexed citations

12.

Griessinger, Emmanuel, Jacques Vargaftig, Stuart Horswell, et al.. (2017). Acute myeloid leukemia xenograft success prediction: Saving time. Experimental Hematology. 59. 66–71.e4. 16 indexed citations

13.

Griessinger, Emmanuel, Fernando Anjos‐Afonso, Jacques Vargaftig, et al.. (2016). Frequency and Dynamics of Leukemia-Initiating Cells during Short-term Ex Vivo Culture Informs Outcomes in Acute Myeloid Leukemia Patients. Cancer Research. 76(8). 2082–2086. 19 indexed citations

14.

Miraki‐Moud, Farideh, Fernando Anjos‐Afonso, Katharine Hodby, et al.. (2013). Acute myeloid leukemia does not deplete normal hematopoietic stem cells but induces cytopenias by impeding their differentiation. Proceedings of the National Academy of Sciences. 110(33). 13576–13581. 108 indexed citations

15.

Rouault‐Pierre, Kevin, Lourdes López-Onieva, Katie Foster, et al.. (2013). HIF-2α Protects Human Hematopoietic Stem/Progenitors and Acute Myeloid Leukemic Cells from Apoptosis Induced by Endoplasmic Reticulum Stress. Cell stem cell. 13(5). 549–563. 143 indexed citations

16.

Dieu, Rifca Le, David Taussig, T. Andrew Lister, & John G. Gribben. (2009). Negative immunomagnetic selection of T cells from peripheral blood of presentation AML specimens. Journal of Immunological Methods. 348(1-2). 95–100. 4 indexed citations

17.

Taussig, David, Farideh Miraki‐Moud, Fernando Anjos‐Afonso, et al.. (2008). Anti-CD38 antibody–mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells. Blood. 112(3). 568–575. 278 indexed citations

18.

Taussig, David. (2005). Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. Blood. 106(13). 4086–4092. 284 indexed citations

19.

Foran, James M., A. J. Norton, David Taussig, et al.. (2001). Loss of CD20 expression following treatment with rituximab (chimaeric monoclonal anti‐CD20): a retrospective cohort analysis. British Journal of Haematology. 114(4). 881–883. 88 indexed citations

20.

Taussig, David, et al.. (1998). Clinical Regression and Remission of Primary Refractory Angiocentric Lymphoma Following Autologous Tumour Peptide Antigen-charged Dendritic Cells After High-dose Chemotherapy and Autologous Stem Cell Rescue. Hematology. 3(4). 277–289. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact